The present application is directed to lipid-drug complexes and related methods for producing stable lipid-drug complexes at or near the neutral pH range and administering pharmaceutical lipid-drug complexes to patients. In certain examples, the lipid-drug complex has a lipid-to-drug molar ratio of approximately 3:1. In certain examples, the lipid-drug complex may have lipid-to-drug molar ratios of less than 3:1 to 10:1 or higher. The present application is also directed to methods of administering a drug to a patient though subcutaneous injection of the lipid-drug complexes into particular tissues to effect higher localized concentrations of the at least one drug. Lipid-anti-HIV-drug complexes can be subcutaneously injected into the lymphoid tissue of a HIV-infected mammalian subject via the lymphatic vessels to deliver high concentrations of stable lipid-anti-HIV-drug complexes, rather than delivery of the anti-HIV drug intravenously via the blood stream which will eventually reach the lymphatic system at lower concentrations.
